Implementation of Early Next-Generation Sequencing for Inborn Errors of Immunity: A Prospective Observational Cohort Study of Diagnostic Yield and Clinical Implications in Dutch Genome Diagnostic Centers.
Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Early Diagnosis
Female
Genetic Testing
/ statistics & numerical data
High-Throughput Nucleotide Sequencing
/ statistics & numerical data
Humans
Infant
Infant, Newborn
Male
Middle Aged
Molecular Diagnostic Techniques
/ statistics & numerical data
Netherlands
/ epidemiology
Prevalence
Primary Immunodeficiency Diseases
/ diagnosis
Prospective Studies
Time Factors
Young Adult
clinical implication
diagnostic yield
gene panel
inborn errors of immunity
next-generation sequencing
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
09
2021
accepted:
01
12
2021
entrez:
7
1
2022
pubmed:
8
1
2022
medline:
15
2
2022
Statut:
epublish
Résumé
Inborn errors of immunity (IEI) are a heterogeneous group of disorders, affecting different components of the immune system. Over 450 IEI related genes have been identified, with new genes continually being recognized. This makes the early application of next-generation sequencing (NGS) as a diagnostic method in the evaluation of IEI a promising development. We aimed to provide an overview of the diagnostic yield and time to diagnosis in a cohort of patients suspected of IEI and evaluated by an NGS based IEI panel early in the diagnostic trajectory in a multicenter setting in the Netherlands. We performed a prospective observational cohort study. We collected data of 165 patients with a clinical suspicion of IEI without prior NGS based panel evaluation that were referred for early NGS using a uniform IEI gene panel. The diagnostic yield was assessed in terms of definitive genetic diagnoses, inconclusive diagnoses and patients without abnormalities in the IEI gene panel. We also assessed time to diagnosis and clinical implications. For children, the median time from first consultation to diagnosis was 119 days versus 124 days for adult patients (U=2323; p=0.644). The median turn-around time (TAT) of genetic testing was 56 days in pediatric patients and 60 days in adult patients (U=1892; p=0.191). A definitive molecular diagnosis was made in 25/65 (24.6%) of pediatric patients and 9/100 (9%) of adults. Most diagnosed disorders were identified in the categories of immune dysregulation (n=10/25; 40%), antibody deficiencies (n=5/25; 20%), and phagocyte diseases (n=5/25; 20%). Inconclusive outcomes were found in 76/165 (46.1%) patients. Within the patient group with a genetic diagnosis, a change in disease management occurred in 76% of patients. In this cohort, the highest yields of NGS based evaluation for IEI early in the diagnostic trajectory were found in pediatric patients, and in the disease categories immune dysregulation and phagocyte diseases. In cases where a definitive diagnosis was made, this led to important disease management implications in a large majority of patients. More research is needed to establish a uniform diagnostic pathway for cases with inconclusive diagnoses, including variants of unknown significance.
Identifiants
pubmed: 34992599
doi: 10.3389/fimmu.2021.780134
pmc: PMC8724043
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
780134Investigateurs
Aerde van Kj
(AV)
Altenburg J
(A)
Armbrust W
(A)
Barendregt Bh
(B)
Berg van den Jm
(BVD)
Bredius Rgm
(B)
Buddingh Ep
(B)
Burg van der M
(BV)
Ellerbroek Pm
(E)
Ernst Rf
(E)
Fraaij Pla
(F)
Hermans M
(H)
Hoischen A
(H)
Hout van der Ah
(HV)
Jansen Mha
(J)
Jolink H
(J)
Jonkers Re
(J)
Laar van Jam
(LV)
Leeuw de K
(L)
Legger Ge
(L)
Leijten Efa
(L)
Limper M
(L)
Lindemans Ca
(L)
Oever Ten J
(OT)
Pieterse M
(P)
Rombach Sm
(R)
Rossum van Amc
(RV)
Rutgers A
(R)
Santen Gwe
(S)
Schölvinck Eh
(S)
Simon A
(S)
Stol K
(S)
Vervenne Rml
(V)
Informations de copyright
Copyright © 2021 Elsink, Huibers, Hollink, Simons, Zonneveld-Huijssoon, van der Veken, Leavis, Henriet, van Deuren, van de Veerdonk, Potjewijd, Berghuis, Dalm, Vermont, van de Ven, Lambeck, Abbott, van Hagen, de Bree, Kuijpers, Frederix, van Gijn, van Montfrans and the Genetics First for Primary Immunodeficiency Disorders Consortium.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Med. 2018 Mar;50(2):91-109
pubmed: 29027470
Lancet. 2010 May 15;375(9727):1749-51
pubmed: 20434765
Clin Rev Allergy Immunol. 2021 Oct;61(2):226-235
pubmed: 33818703
Front Immunol. 2014 Nov 03;5:531
pubmed: 25404929
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
NPJ Genom Med. 2021 Mar 25;6(1):25
pubmed: 33767182
J Allergy Clin Immunol. 2016 Oct;138(4):957-969
pubmed: 27720020
Genome Med. 2019 Jun 17;11(1):38
pubmed: 31203817
Annu Rev Pathol. 2018 Jan 24;13:27-49
pubmed: 28934563
Chin J Cancer. 2012 Oct;31(10):463-70
pubmed: 22980418
Hum Genet. 2013 Oct;132(10):1077-130
pubmed: 23820649
Nature. 2020 Jul;583(7814):90-95
pubmed: 32499645
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
J Allergy Clin Immunol. 2021 May 12;:
pubmed: 33991581
Pediatrics. 2013 Nov;132(5):e1440-4
pubmed: 24101757
Eur J Hum Genet. 2015 Sep;23(9):1270
pubmed: 26269248
Genet Med. 2018 Nov;20(11):1374-1386
pubmed: 29517769
J Clin Immunol. 2018 Jan;38(1):129-143
pubmed: 29226301
Int J Neonatal Screen. 2018 Dec 12;4(4):40
pubmed: 33072960
Eur J Hum Genet. 2021 Jan;29(1):20-28
pubmed: 32733070
J Allergy Clin Immunol. 2014 Feb;133(2):529-34
pubmed: 24139496
J Clin Immunol. 2017 Jan;37(1):85-91
pubmed: 27815752
Blood. 2020 Feb 27;135(9):656-667
pubmed: 31942606
N Engl J Med. 2021 Feb 4;384(5):440-451
pubmed: 33471974
Hematol Oncol Clin North Am. 2015 Oct;29(5):943-59
pubmed: 26461153
Pediatr Ann. 2017 Aug 1;46(8):e309-e313
pubmed: 28806468
Front Immunol. 2017 Sep 28;8:1190
pubmed: 29033928
Am J Hum Genet. 2016 Jul 7;99(1):247
pubmed: 27392081
J Allergy Clin Immunol. 2018 Apr;141(4):1450-1458
pubmed: 28916186
Hum Mutat. 2013 Oct;34(10):1313-21
pubmed: 23776008
J Clin Immunol. 2019 Aug;39(6):577-591
pubmed: 31250335
PLoS One. 2015 Oct 13;10(10):e0140473
pubmed: 26461272
Clin Immunol. 2020 Apr;213:108359
pubmed: 32035178
J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S571-81
pubmed: 12592303
Pediatr Int. 2016 Sep;58(9):817-25
pubmed: 27289085
J Allergy Clin Immunol. 2021 Feb;147(2):723-726
pubmed: 32888943
Front Immunol. 2019 Apr 11;10:316
pubmed: 31031743
J Clin Immunol. 2021 Apr;41(3):666-679
pubmed: 33598806
Front Immunol. 2016 Nov 07;7:466
pubmed: 27872624
J Clin Immunol. 2018 Jan;38(1):96-128
pubmed: 29226302
J Allergy Clin Immunol. 2016 Jun;137(6):1780-1787
pubmed: 26915675
Clin Rev Allergy Immunol. 2021 Oct;61(2):212-225
pubmed: 33666867
Genome Med. 2021 Apr 14;13(1):59
pubmed: 33853652